The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.

Inclusion Criteria:

• mild to moderate hypertension
• naive to antihypertensive medication or on two or less antihypertensive medications
• impaired glucose tolerance
• mild obesity

Exclusion Criteria:

• Diagnosis of Type 1 or Type 2 diabetes
• History of severe heart failure
• AST, ALT levels more than twice the normal range